EUVIMEDEUVIMED entdecken
Crossref

The Italian experience on liver transplantation for unresectable peri-hilar cholangiocarcinoma: a national survey and future perspectives

Enrico Gringeri, Alessandro Furlanetto, Ilaria Billato, Matteo Cescon, Luciano De Carlis, Vincenzo Mazzaferro, Renato Romagnoli, Paolo De Simone, Marco Vivarelli, Fabrizio Di Benedetto, Matteo Ravaioli, Andrea Lauterio und 13 weitere

Updates in Surgery · 2024-11 · 76 (7) · 2505-2513

DOI: 10.1007/s13304-024-01889-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Updates in Surgery, online erschienen am 29.08.2024. Verfasst von Enrico Gringeri und 24 weiteren Autor:innen. Beteiligte Einrichtung: General Surgery 2, Hepato-biliary-Pancreatic Surgery and Liver Transplantation Unit, Padua University Hospital, Padua, Italy. enrico.gringeri@unipd.i…. Hauptthemen laut MEDLINE: Bile Duct Neoplasms, Klatskin Tumor, Liver Transplantation, Neoadjuvant Therapy. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Liver transplantation (LT) was considered an ineffective treatment for perihilar cholangiocarcinoma (pCCA) until the successful experience of the Mayo Clinic, proposing a protocol with strict inclusion criteria and neoadjuvant radio-chemotherapy. Since 2015, pCCA is considered an indication for LT in Italy only in the context of controlled prospective studies. We performed a survey among the 22 Italian Liver Transplant Centers to assess the results of LT for pCCA. Eight centers reported 53 cases from 1986 to 2021 (Bologna 12, Padova 10, Niguarda 10, Milano Tumori 8, Torino 5, Pisa 4, Ancona 2, Modena 2). Patients were divided according to whether they recieved neoadjuvant radio-chemotherapy (Group 1, 25 cases) or not (Group 2, 28 cases). Eleven patients were transplanted without neoadjuvant treatment after 2015. Overall survival at 1, 3 and 5 years was 83.8%, 56.6% and 50.6% in Group 1 and 72.4%, 41.4% and 35.5% in Gropu 2 (p = 0.13). Recurrence-free survival at 1, 3, and 5 years was 91.2%, 61.1% and 47.2% in Group 1 and 58.2%, 42.2%, and 36.1% in Group 2 (p = 0.16). A competing risk regression analysis showed a 5-year risk of cancer-related death of 19% for patients in Group 1 against 62.3% in Group 2, with a hazard ratio of 0.31 (95%CI [0.10-0.98], p 0.047). This survey promoted a discussion about the limitations of the Mayo protocol and set the basis for the adoption of a new nationwide protocol (LITHALICA-NCT06125769), having the same inclusion criteria but proposing standard of care chemotherapy as neoadjuvant regimen.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bile Duct NeoplasmsKlatskin TumorLiver TransplantationNeoadjuvant TherapyAgedFemaleHumansMaleMiddle AgedItalySurveys and QuestionnairesSurvival RateTreatment OutcomeClinical Trials as Topic

Stichwörter der Autor:innen

Biliary tumorsLiverLiver transplantationNeoadjuvant therapyPerihilar cholangiocarcinoma

Autor:innen und Institutionen

  • General Surgery 2, Hepato-biliary-Pancreatic Surgery and Liver Transplantation Unit, Padua University Hospital, Padua, Italy. enrico.gringeri@unipd.it.
  • Department of Surgery Oncology and Gastroenterology, University of Padova, Via Giustiniani 2, 35128, Padua, Italy. enrico.gringeri@unipd.it.
  • General Surgery 2, Hepato-biliary-Pancreatic Surgery and Liver Transplantation Unit, Padua University Hospital, Padua, Italy.
  • Department of Surgery Oncology and Gastroenterology, University of Padova, Via Giustiniani 2, 35128, Padua, Italy.
  • Department of General Surgery and Transplantation, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Department of General Surgery and Transplantation, Niguarda Ca' Granda Hospital, 20162, Milan, Italy.

Zitieren

APA

Gringeri, E., Furlanetto, A., Billato, I., Cescon, M., De Carlis, L., Mazzaferro, V., Romagnoli, R., De Simone, P., Vivarelli, M., Di Benedetto, F., Ravaioli, M., Lauterio, A., Sposito, C., Patrono, D., Ghinolfi, D., Moccheggiani, F., Di Sandro, S., D'Amico, F. E., Lanari, J., …, & Cillo, U. (2024). The Italian experience on liver transplantation for unresectable peri-hilar cholangiocarcinoma: a national survey and future perspectives. Updates in Surgery, 76(7), 2505-2513. https://doi.org/10.1007/s13304-024-01889-1

Vancouver

Gringeri E, Furlanetto A, Billato I, Cescon M, De Carlis L, Mazzaferro V, et al. The Italian experience on liver transplantation for unresectable peri-hilar cholangiocarcinoma: a national survey and future perspectives. Updates in Surgery. 2024;76(7):2505-2513. doi:10.1007/s13304-024-01889-1

BibTeX
@article{Gringeri2024,
  author = {Gringeri, Enrico and Furlanetto, Alessandro and Billato, Ilaria and Cescon, Matteo and De Carlis, Luciano and Mazzaferro, Vincenzo and Romagnoli, Renato and De Simone, Paolo and Vivarelli, Marco and Di Benedetto, Fabrizio and Ravaioli, Matteo and Lauterio, Andrea and Sposito, Carlo and Patrono, Damiano and Ghinolfi, Davide and Moccheggiani, Federico and Di Sandro, Stefano and D'Amico, Francesco Enrico and Lanari, Jacopo and Gambato, Martina and Trapani, Silvia and Bergamo, Francesca and Cardillo, Massimo and Burra, Patrizia and Cillo, Umberto},
  title = {The Italian experience on liver transplantation for unresectable peri-hilar cholangiocarcinoma: a national survey and future perspectives},
  journal = {Updates in Surgery},
  year = {2024},
  volume = {76},
  number = {7},
  pages = {2505--2513},
  doi = {10.1007/s13304-024-01889-1}
}
Kostenlos starten →